Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zithromax™ · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Zithromax™ (azithromycin) 500mg tablets | DRUG | - |
| Endoscopic Sinus Surgery | PROCEDURE | - |
| Blood sampling for hematology | PROCEDURE | - |
| Blood sampling for plasma chemistry profile | PROCEDURE | - |
| Serum pregnancy test (for women of child-bearing potential) | PROCEDURE | - |
Inclusion Criteria: * Subjects considered by the Principal Investigator as an appropriate candidate for endoscopic sinus surgery, e.g., for the removal of the thickened and diseased mucosal tissue that blocks the ostiomeatal complex (OMC). Exclusion Criteria: * Known or suspected hypersensitivity...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE3 | 611 |
| Optinose US Inc. | OPTN | 1 | PHASE3 | OPN-375 |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | - | DUPIXENT |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Dupilumab |
Zithromax is a small molecule antibiotic being studied for the treatment of sinusitis, an inflammation of the sinus cavities. It is currently in Phase 2 clinical development for this indication. The drug is administered orally, with studies evaluating doses such as a single 2g dose or 500mg tablets.
Zithromax is developed by Pfizer, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical research to evaluate the drug's use in patients with sinusitis.
Zithromax is in Phase 2 clinical development for the treatment of sinusitis. It is an investigational drug for this indication and has not been approved by regulatory authorities for this use. One Phase 2 trial has been completed to assess the drug's levels in nasal tissue and blood.
Zithromax has one completed Phase 2 clinical trial registered as NCT00232154. This study enrolled 72 participants in the United States and measured drug levels in nasal tissue and blood after taking a single 2g dose or 500mg tablets. The trial was uncontrolled and not double-blinded.
Zithromax is a brand name for the antibiotic azithromycin. In the context of sinusitis, it is being studied as a small molecule therapy. The clinical trial NCT00232154 evaluates the drug's penetration into nasal tissue and blood levels following oral administration.